Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


First published on May 23, 2007
A more recent version of this article appeared on July 1, 2007
Neuro Oncol 2007, DOI:10.1215/15228517-2007-004
This Article
Right arrow Advance Publication Full Text (PDF)
Right arrow All Versions of this Article:
9/3/364    most recent
15228517-2007-004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Neill, B. P.
Right arrow Articles by Giannini, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Copyright 2007 by the Society for Neuro-Oncology

Received August 9, 2006
Accepted October 23, 2006

Clinical Investigations

EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil

Brian Patrick O'Neill 1*, Steven Vernino 2, Ahmet Dogan 3, Caterina Giannini 3

1 Department of Neurology, Mayo Clinic and Foundation and the Mayo Clinic Cancer Center, Rochester, MN 55905, USA
2 Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
3 Department of Laboratory Medicine, Mayo Clinic and Foundation and the Mayo Clinic Cancer Center, Rochester, MN 55905, USA

* To whom correspondence should be addressed. E-mail: boneill{at}mayo.edu.


   Abstract

Epstein-Barr virus (EBV)-associated lymphoid proliferations are a well-recognized complication of congenital or acquired systemic immunosuppression. The CNS is a frequent site for development of such lymphoid proliferations. We describe the clinical, imaging, and pathologic observations of a CNS disorder histologically similar to posttransplantation lymphoproliferative disorder that occurred in four patients with autoimmune disease treated with mycophenolate mofetil (MM). Two patients had polymorphous lymphoplasmacytic infiltration of brain parenchyma, and two had monomorphous infiltrations consistent with diffuse large B-cell lymphoma. In situ hybridization for EBV-encoded RNA was positive in all four patients. All patients improved after MM withdrawal and the use of rituximab. Because of a favorable toxicity profile, MM is now being used as steroid-sparing immunomodulatory therapy in autoimmune disorders. Based on our experience presented herein, we recommend caution in patient selection for MM and strict surveillance of those patients with autoimmune disorders who receive MM.

Key Words: CNS, EBV, lymphoproliferation, mycophenolate, primary CNS lymphoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
N. Kumar, P. Sandroni, D. P. Steensma, H. S. Luthra, and T. M. Habermann
POLYRADICULOPATHY DUE TO METHOTREXATE-INDUCED EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISORDER
Neurology, November 11, 2008; 71(20): 1644 - 1645.
[Full Text] [PDF]




  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


Copyright 2007 by Society for Neuro-Oncology